APOBEC3B and breast cancer: The gain-of-function experiments in our engineered MCF10A cells also suggest that there may be no other repressive mechanisms during all other cell cycle phases and that aberrant pathway activation during proliferation likely explains A3B overexpression observed in a significant proportion of breast cancers.